Cesar Guzman Huancas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cesar Guzman Huancas has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Brendan G. Dwyer
Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine
17 shared publications - Calvin J. Kuo
Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
17 shared publications - Christine Wenjie Zhou
Stanford Cancer Institute, Stanford, California
17 shared publications - Daniel Fernandez
Stanford University
17 shared publications - Gianna M. Colombo
Stanford School of Medicine
17 shared publications - Gregory W. Charville
Stanford University School of Medicine
17 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows proteomic and imaging analyses demonstrating TRIM21-dependent rapid degradation of nuclear pore complex proteins by PRLX and JWZ-8-103, including LC-MS/MS profiling, structural mapping, and confocal microscopy.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows proteomic and imaging analyses demonstrating TRIM21-dependent rapid degradation of nuclear pore complex proteins by PRLX and JWZ-8-103, including LC-MS/MS profiling, structural mapping, and confocal microscopy.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Presents pharmacokinetic analyses and in vivo efficacy of TRIM21-targeting compounds in organoid and xenograft models, including immunoblotting, plasma concentration profiles, and tumor growth studies.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Presents pharmacokinetic analyses and in vivo efficacy of TRIM21-targeting compounds in organoid and xenograft models, including immunoblotting, plasma concentration profiles, and tumor growth studies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Cancer cells are acutely dependent on nuclear transport due to elevated transcriptional activity, suggesting an unrealized opportunity for selective therapeutic inhibition of the nuclear pore complex (NPC). Through large-scale phenotypic profiling of cancer cell lines, genome-scale functional genomic modifier screens, and mass spectrometry–based proteomics, we discovered that the clinical drug PRLX-93936 is a molecular glue that binds and reprograms the TRIM21 ubiquitin ligase to degrade the NPC. Upon compound-induced TRIM21 recruitment, the nuclear pore is ubiquitylated and degraded, resulting in the loss of short-lived cytoplasmic mRNA transcripts and the induction of cancer cell apoptosis. Direct compound binding to TRIM21 was confirmed via surface plasmon resonance and X-ray crystallography, whereas compound-induced TRIM21–nucleoporin complex formation was demonstrated through multiple orthogonal approaches in cells and in vitro. Phenotype-guided optimization yielded compounds with 10-fold greater potency and drug-like properties, along with robust pharmacokinetics and efficacy against pancreatic cancer xenografts and patient-derived organoids.Significance:This study establishes the cancer therapeutic potential of optimized TRIM21 molecular glues to degrade the NPC and underscores the value of reexamining drugs with previously unknown mechanisms using current technologies.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Cancer cells are acutely dependent on nuclear transport due to elevated transcriptional activity, suggesting an unrealized opportunity for selective therapeutic inhibition of the nuclear pore complex (NPC). Through large-scale phenotypic profiling of cancer cell lines, genome-scale functional genomic modifier screens, and mass spectrometry–based proteomics, we discovered that the clinical drug PRLX-93936 is a molecular glue that binds and reprograms the TRIM21 ubiquitin ligase to degrade the NPC. Upon compound-induced TRIM21 recruitment, the nuclear pore is ubiquitylated and degraded, resulting in the loss of short-lived cytoplasmic mRNA transcripts and the induction of cancer cell apoptosis. Direct compound binding to TRIM21 was confirmed via surface plasmon resonance and X-ray crystallography, whereas compound-induced TRIM21–nucleoporin complex formation was demonstrated through multiple orthogonal approaches in cells and in vitro. Phenotype-guided optimization yielded compounds with 10-fold greater potency and drug-like properties, along with robust pharmacokinetics and efficacy against pancreatic cancer xenografts and patient-derived organoids.Significance:This study establishes the cancer therapeutic potential of optimized TRIM21 molecular glues to degrade the NPC and underscores the value of reexamining drugs with previously unknown mechanisms using current technologies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows SPR binding analyses of PRLX and analogues to TRIM21 PRYSPRY, and immunoblot verification of TRIM21 expression in knockout cells reconstituted with TRIM21 cDNAs.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows SPR binding analyses of PRLX and analogues to TRIM21 PRYSPRY, and immunoblot verification of TRIM21 expression in knockout cells reconstituted with TRIM21 cDNAs.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows immunoblot and live-cell imaging analyses assessing washout-based cytotoxicity of PRLX and JWZ-8-103 in PANC-1 and hTERT RPE-1 cells.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows immunoblot and live-cell imaging analyses assessing washout-based cytotoxicity of PRLX and JWZ-8-103 in PANC-1 and hTERT RPE-1 cells.